EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy GLASGOW, United Kingdom, March 28, 2023 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EBX”), a clinical stage biotechnology company focussed on developing best-in-class full-spectrum microbiome...